IMPEKLO

Peak

clobetasol propionate

NDATOPICALLOTION
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7

Clinical Trials (5)

NCT05724446Phase 3Recruiting

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Started Dec 2022
60 enrolled
Cataracts Infantile
NCT04246801Phase 3Completed

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

Started Jun 2020
250 enrolled
Cataract
NCT04249076Phase 3Completed

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

Started Jun 2020
215 enrolled
Cataract
NCT01323673Phase 4Completed

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

Started Nov 2010
125 enrolled
Dermatitis, Chronic
NCT00828464Phase 4Completed

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

Started Oct 2008
30 enrolled
Hand Dermatosis